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Background and purpose: The modified Rankin Scale (mRS) was designed to 
measure poststroke recovery but is often used to describe pre-stroke disability. We 
sought to evaluate three aspects of pre-stroke mRS: validity as a measure of pre-stroke 
disability; prognostic accuracy and association of pre-stroke mRS scores, and process 
of care.
Methods: We used data from a large, UK clinical registry. For analysis of validity, we 
compared pre-stroke mRS against other markers of pre-stroke function (age, comorbid-
ity index, care needs). For analysis of prognostic accuracy, we described univariable and 
multivariable models comparing pre-stroke mRS and other prognostic variables against 
a variety of outcomes (early and late mortality, length of stay, institutionalization, incident 
complications). Finally, we described association of pre-stroke mRS and components of 
evidence-based stroke care (early neuroimaging, admission to stroke unit, assessment 
of swallow).
results: We analyzed data of 2,491 stroke patients. Concurrent validity analyses 
suggested statistically significant, but modest correlations between pre-stroke mRS 
and chosen variables (rho >0.40; p < 0.0001 for all). Every point increase of pre-stroke 
mRS was associated with poorer outcomes for our prognostic variables (unadjusted 
p <  0.001). This association held when corrected for other covariates. For example, 
pre-stroke mRS 4–5 odds ratio (OR): 6.84 (95% CI: 4.24–11.03) for 1  year mortality 
compared to mRS 0 in adjusted model. There was a difference between pre-stroke 
mRS and treatment, with higher pre-stroke mRS more likely to receive evidence- 
based care.
conclusion: Results suggest that pre-stroke mRS has some concurrent validity and 
is a robust predictor of prognosis. This association is not explained by the influence of 
pre-stroke mRS on care pathways.
Keywords: modified rankin scale, disability, stroke, outcome, complications, prognosis
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inTrODUcTiOn
Disability and comorbidity are common in older adult populations. 
Demographic change will see increasing absolute numbers of 
older people with some degree of disability and comorbidity 
(1). Although stroke is a common cause of disability, many who 
experience stroke already have premorbid functional problems 
(2). To understand post stroke recovery and to plan realistic 
rehabilitation goals, it is important to have a method of describing 
pre-stroke disability.
As well as clinical utility, robust measures of pre-stroke func-
tion are also needed for research. Pre-stroke disability is often 
employed as exclusion criterion or case mix adjuster for trials 
and international registries (3, 4). This approach recognizes that 
even the best treatment is unlikely to improve function to better 
than the pre-stroke state. Pre-stroke disability may also have 
important prognostic utility, although data on this have been 
conflicting (5, 6). Many acute stroke risk stratification scales 
feature pre-stroke disability as a covariate (7, 8).
While the need to describe pre-stroke function is apparent, the 
method of achieving this is less certain. The modified Rankin scale 
(mRS) is a measure of global disability that is commonly used as a 
functional outcome for stroke studies (9). The mRS was designed 
to assess poststroke recovery levels and the wording of the original 
scale assumes a comparison with the pre-stroke state. The scale 
has also been used to evaluate pre-stroke disability levels (10). Pre-
stroke mRS has been used extensively in research, audit, and service 
planning. For example, patients were excluded from seminal trials 
of acute stroke therapy if pre-stroke mRS was greater than a certain 
threshold (3, 4). In the UK national stroke audit, pre-stroke mRS is 
one of the core descriptors collected (11). In practice, decisions on 
treatment are often based on premorbid function (12).
Use of pre-stroke mRS for these purposes is potentially pro-
blematic as the clinical properties of the pre-stroke mRS have 
not been as thoroughly investigated as traditional poststroke 
mRS (13). The wording of the various levels of the scale, and the 
criteria used to distinguish one mRS grade from another, assume 
a previous stroke. This can cause issues in application when the 
scale is used to measure function before a stroke event. These 
issues are particularly problematic at lower mRS values, where 
comparison is made to the pre-stroke state. Although there is 
guidance on pre-stroke mRS scoring in those with a pre vious 
stroke event (14, 15), there is no internationally accepted con-
sensus on how to use mRS as a pre-stroke measure in patients 
who have never had a previous stroke (14, 16).
Based on the current usage of pre-stroke mRS, key questions 
emerge. If pre-stroke mRS is used to assess prevalent disability, 
is it a valid measure of this construct? If pre-stroke disability 
is used as a component item in prognostic models, what is the 
independent contribution of pre-stroke mRS to outcome? If pre-
stroke mRS is associated with outcome, can this be explained by 
differing process of care?
We aimed to use UK multicentre, clinical cohort to answer 
the above important and relevant research questions. Therefore, 
the specific aims of this study were:
 (1) To assess the “validity” of pre-stroke mRS by comparison 
with other related disability metrics.
 (2) To assess association of pre-stroke mRS with short and longer 
term mortality prognosis in a “real world” sample.
 (3) To assess if pre-stroke mRS is associated with a differing 
process of care.
MaTerials anD MeThODs
Population
We used the data held in the Anglia Stroke Clinical Network 
Evaluation Study (ASCNES). ASCNES was a multi-center, 
prospective cohort study. ASCNES collected clinical data from 
sequential stroke admissions across eight acute NHS (National 
Health Service) trusts in the East of England, UK (Norfolk, 
Suffolk, and Cambridgeshire). Data collection was from October 
2009 to September 2011 inclusive. Data capture included a 1 year 
follow-up.
The full details of ASCNES have been described previously 
(17). In brief, included patients were aged over 18  years, with 
stroke confirmed and phenotyped by expert multidisciplinary 
clinical assessment. Our population included both first ever 
stroke and recurrent stroke and all included patients were treated 
as per institutional practice and stroke guidelines. Relevant 
institutional and ethical approvals for use of these data were 
in place.
mrs assessment
The ASCNES dataset was based on the modification of the Basic 
European Stroke Register Database but including process of 
care measures. Data were collected by clinical staff and trans-
ferred to an electronic database. Pre-stroke mRS was part of the 
ini tial assessment. All mRS assessments (pre- and poststroke) 
were per formed by clinical staff using an unstructured interview 
and based on history taken from patient whenever possible, or 
their significant others/carers. The participating sites offered no 
explicit guidance on applying mRS grades as a pre-stroke measure 
and final score was at the discretion of the assessor.
analyses
We used basic descriptive statistics to describe baseline variables 
of included patients. As pre-stroke mRS was a key variable, we 
compared those with and without pre-stroke mRS against pre-
specified variables of age, sex, NIHSS, stroke type (ischemic or 
haemorrhagic), systolic blood pressure, atrial fibrillation (AF), 
blood glucose, and Oxford Community Stroke Project (OCSP) 
classification.
Validity of Pre-stroke mrs
We described concurrent validity of pre-stroke mRS by compari-
son with other baseline clinical and demographic variables that 
are known to be associated with physical function. Our chosen 
comparators were, age, comorbidity burden assessed by Charlson 
comorbidity index (18), mRS at discharge, pre-stroke residence 
(categorized as: home, sheltered housing, rehabilitation center, 
care home), and receipt of formal care pre-stroke (categorized as: 
lives alone, lives with family, external carers, sheltered housing, 
institutional care).
TaBle 2 | Frequency of pre-stroke mRS score.
Pre-stroke mrs rating score frequency (%)
mRS 0 1,027 (51%)
mRS 1 367 (18%)
mRS 2 207 (10%)
mRS 3 212 (11%)
mRS 4 132 (7%)
mRS 5 56 (3%)
mRS, modified Rankin scale.
TaBle 1 | Summary descriptive statistics of Anglia Stroke Clinical Network 
Evaluation Study data.
Variable N Mean (sD)/
median (iQr)
Min Max
Age (years) 2,487 76.4 (13.1) 18 101
Pre-stroke Rankin 2,001 0 (0–2) 0 (N = 1,027; 
51.3%)
5 (N = 56; 
2.7%)
MEWSa 2,101 1.4 (1.3) 0 7
NIHSSa 673 7 (3–14) 0 36
Systolic BP (mmHg)a 2,406 157.2 (30.5) 60 271
Glucose (mmol/l)a 2,136 7.6 (3.0) 1.4 40.2
N %
aF
No 1,469 59.0
Yes 714 28.7
Missing 308 12.4
stroke type
ICH 320 85.1
Infarct 2,120 12.9
Missing 51 2.0  
Bamford
LACS 520 20.9
PACS 856 34.4
POCS 308 12.4
TACS 473 19.0
Missing 334 13.4
sex
Female 1,311 52.6
Male 1,178 47.3
MEWS, modified early warning score (scale of 0–6+; higher scores indicate greater 
concern for health based on cardinal vital signs; 1–3 = low concern; 4 or 5 = medium 
concern; 6+ = high concern); NIHSS, National Institute of Health Stroke Scale; BP, 
blood pressure; AF, atrial fibrillation; ICH, intracerebral hemorrhage.
aMeasured on admission.
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We described association of pre-stroke mRS with other 
variables using chi-square for proportional data and Spearman 
rank correlation for nominal data. We re-categorized pre-stroke 
residence as “own home” or other (comprising any form of insti-
tutional care) and calculated odds-ratios for each pre-stroke mRS 
grade.
association of Pre-stroke mrs  
and Outcomes
We examined the association between pre-stroke mRS and 
selected outcomes, which included mortality at 7  days and 
1 year, length of stay (days), discharge destination (categorized 
as per our validity analyses), and poststroke complications of 
pneumonia and urinary tract infection. Due to modest numbers 
in pre-stroke mRS 4 and mRS 5, these categories were combined. 
We calculated univariable associations between pre-stroke mRS 
and outcomes of interest with strength of association described 
as odds ratio (OR) or beta for length of stay data. To compare 
pre-stroke mRS with other variables known to have prognostic 
importance, we also described association with outcomes for 
age, sex, stroke type, modified early warning score, glucose, 
AF, and comorbidity. We then calculated OR for pre-stroke 
mRS adjusted for other important prognostic variables (NIHSS, 
age, sex).
association of Pre-stroke mrs  
and Process of care
To describe association between pre-stroke mRS and process of 
care, we selected three aspects of acute stroke care that should be 
standard, are recommended in guidelines, and have been shown to 
have utility regardless of pre-stroke function. Our chosen process 
of care markers were: assessment of swallow (in first 24 h) (19); 
admission to dedicated stroke unit (SU) (days to SU admission 
from hospital admission and dichotomous yes/no) (20); brain 
imaging (days from admission to imaging and dichotomous 
yes/no) (21). Association of swallow test performed; admission 
to SU, and imaging performed with pre-stroke mRS was described 
for each factor using Mann–Whitney, association with catego-
rized time to SU admission (days) and time to imaging (days) was 
described using Cuzik test for trend.
subgroup analyses
Recognizing the difficulty in applying mRS to a population 
with no history of stroke, we performed subgroup analyses, we 
described our validity and prognostic analyses comparing results 
for those with a previous history of stroke against first ever 
strokes. Recognizing that the wording of the lower mRS grades 
make them more difficult to use as a pre-stroke assessment, we 
performed a further subgroup analysis comparing those with 
pre-stroke mRS 0–2 to those with pre-stroke mRS 3–5. Our data-
set included patients admitted to University Teaching Hospitals 
and smaller “General” Hospitals. Sites could plausibly assess 
pre-stroke mRS differently depending on training, exposure to 
research, and staff mix. We tabulated pre-stroke mRS stratified 
by treating center.
resUlTs
A total of 2,491 patients with stroke were included in the ASCNES 
dataset. The mean age was 76.4 years (SD, 13.1), 1,311 (53%) were 
females; 2,120 (85%) had ischemic stroke (Table 1).
Pre-stroke mRS data were available for 2,001 patients. Median 
pre-stroke mRS was 0 (IQR, 0–2; range: 0–5) (Table 2). Pre-stroke 
mRS data were missing for 488 (24.4%) of the sample. There was 
no difference between those with and without mRS data for any 
of our pre-specified variables, other than OCSP where those with 
more severe strokes (TACS) were more likely to have missing 
pre-stroke mRS data (Supplementary Material). Data were also 
missing for those with AF (308; 12.4%), stroke type (51; 2%), and 
Bamford classification (334; 13.4%).
TaBle 4 | Association between factors and death within 1 year.
Unadjusted adjusted
Odds ration (Or) 
(95% ci)
p-Value Or (95% ci) p-Value
Age (by year) 1.08 (1.07, 1.09) <0.001 1.04 (1.02, 1.06) <0.001
Male 0.65 (0.55, 0.77) <0.001 0.79 (0.6, 1.06) 0.111
Pre-stroke 
Rankin
Trend: 
<0.001
Trend: 
<0.001
1 vs 0 2.23 (1.69, 2.94) <0.001 1.88 (1.29, 2.74) 0.001
2 vs 0 2.82 (2.03, 3.92) <0.001 1.85 (1.2, 2.85) 0.005
3 vs 0 5.48 (3.99, 7.51) <0.001 3.43 (2.24, 5.25) <0.001
4 or 5 vs 0 11.97 (8.4, 17.04) <0.001 6.84 (4.24, 11.03) <0.001
ICH 2.28 (1.79, 2.89) <0.001 3.99 (2.69, 5.9) <0.001
MEWS 1.32 (1.23, 1.41) <0.001 1.18 (1.07, 1.31) 0.001
Glucose 1.07 (1.04, 1.10) <0.001 1.06 (1.02, 1.11) 0.008
AF 2.08 (1.73, 2.52) <0.001 1.59 (1.2, 2.12) 0.001
Charlson index 1.37 (1.32, 1.43) <0.001 1.17 (1.08, 1.26) <0.001
ICH, intracerebral hemorrhage; MEWS, Modified Early Warning Score; AF, atrial 
fibrillation.
TaBle 3 | Association of pre-stroke Rankin and other markers of function.
Factor association p-Value
Age 0.40 (0.36, 0.44)a <0.0001
mRs on discharge 0.50 (0.46, 0.53)a <0.0001
Pre-stroke residence 995.52 <0.0001
Pre-stroke formal care received 761.12 <0.0001
Charlson comorbidity index 0.41 (0.37, 0.44)a <0.0001
aSpearman rank correlation coefficient (95% CI); two chi-squared test (DOF = 9).
mRS, modified Rankin scale.
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Validity of Pre-stroke mrs
Of included patients, 1,240 (49.8%) were living alone with no 
carers prior to admission. Median Charlson comorbidity index 
was 5 (IQR, 4–6). Age at time of stroke, discharge mRS, pre-stroke 
residence, pre-stroke care, and Charlson comorbidity index were 
all associated with pre-stroke mRS (rho >0.40 for continuous 
vari ables, p <  0.0001) (Table  3). Every point increase in pre-
stroke mRS was associated with an increased association of 
living in institutional care pre-stroke. For example, comparing 
pre-stroke mRS 0 and 5, OR of institutional care pre-stroke was 
73 [95% confidence interval (95% CI): 37–143] (Supplementary 
Material).
On our subgroup analyses looking at those with previous 
stroke and those with lower pre-stroke mRS values, there was 
no clear and consistent difference between groups. Inspection 
of pre-stroke mRS classification by treating center suggested 
differential scoring at lower mRS grades between sites. The large 
number of sites and modest number of participants in certain 
grades precluded formal comparative analyses (Supplementary 
Material).
association of Pre-stroke mrs  
and Outcomes
Mean length of stay was 16 days (SD, 20). Discharge to home, with 
no carers was recorded in 689 (28%); 400 (16%) were transferred 
from acute hospital to a rehabilitation facility. One year mortal-
ity was 770 (31%); 7-day mortality 265 (11%). Of poststroke 
complications, 288 (12%) developed pneumonia and 146 (6%) 
urinary tract infection. Every point increase in pre-stroke mRS 
was associated with greater numbers of poor outcomes for all 
our chosen outcomes. Strength of association was comparable to 
or higher than other known prognostic variables. Associations 
held when corrected for other covariates. For example, pre-stroke 
mRS score of 4 or 5 OR: 6.84 (95% CI: 4.24–11.03) compared 
to 0 in adjusted model [Table 4 (1-year mortality); Supplementary 
Material other outcomes].
On our subgroup analyses looking at those with previous 
stroke and those with lower pre-stroke mRS values, there was no 
clear and consistent difference between groups (Supplementary 
Material).
Pre-stroke mrs and Processes of care
Of 2,383 patients with relevant data, 1,674 (70%) had a swallow 
test performed; 2,287 (96%) had brain imaging, of whom 1,520 
(64%) were scanned within 24 h; and 1,886 (79%) were admitted 
to a SU of whom 1,162 (49%) were admitted on the same day. 
There was a difference in pre-stroke mRS between those who 
received swallow assessment (p  =  0.04) and brain imaging 
(p = 0.0003), but not admission to ASU (p = 0.21). This differ-
ence favored those with greater disability, i.e., higher pre-stroke 
mRS was more likely to receive these evidence-based aspects of 
care. There was no apparent difference in time to SU admission 
or imaging by pre-stroke mRS.
DiscUssiOn
We sought to assess some of the key clinical properties of the 
pre-stroke mRS in order to address important questions as to its 
use in clinical research and practice. According to our results, the 
pre-stroke mRS has a validity that is close to what is considered 
as fair (<0.5) (20), albeit in the absence of a true gold standard 
for pre-stroke function, these analyses are open to interpretation 
and the correlation described may be acceptable. Pre-stroke mSR 
is a potential tool for predicting prognostic outcome following 
stroke and the relationship between pre-stroke mRS scores and 
prognosis is not related to variations in patient care pathways.
Arguably, the most important property of pre-stroke mRS is 
validity; the scale is of little utility if it does not measure what it 
purports to measure. We assessed concurrent validity and found 
that the pre-stroke mRS demonstrated significant associations 
with all our chosen measures that should reflect pre-stroke dis-
ability. Although significant, the correlation we demonstrated 
was at best moderate in strength. This finding is similar to that of 
Fearon (6) who found moderate correlations between pre-stroke 
mRS and pre-stroke comorbidity and frailty, but not pre-stroke 
care needs. Although there are concerns that pre-stroke mRS 
may not be suited to first stroke events or those with good func-
tion pre-stroke, our subgroup analyses did not find any convinc-
ing evidence of this. Our results should reassure clinicians and 
researchers that pre-stroke mRS does capture pre-stroke function, 
but the moderate associations suggest that there may be scope for 
further improvement.
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Our results demonstrate that the pre-stroke mRS is a potential 
prognostic indicator. Although pre-stroke mRS is widely accepted 
to be an indicator of prognosis, there has been very little pub-
lished work to confirm this. We found that as the pre-stroke mRS 
score increased, patients were more likely to experience negative 
outcomes, and this pattern was consistent across all of our chosen 
outcome measures (LOS, discharge destination, mortality, and 
complications after stroke). Furthermore, the strength of asso-
ciation of the pre-stroke mRS with each outcome variable was 
comparable or greater than that of all of our other prognostic 
variables, suggesting that the prognostic utility of pre-stroke mRS 
is at least as strong as other commonly used indicators of progno-
sis. These findings are broadly consistent with those of Kwok et al. 
(5) who also found that pre-stroke mRS was a robust predictor 
of poststroke outcome, as measured by mortality and length 
of stay. Our findings also extend the prognostic predictability of 
the pre-stroke mRS to that of eventual discharge destination and 
the prevalence of complications poststroke.
Importantly, we also found that the association between 
pre-stroke mRS and outcome cannot be explained by differing 
process of care. Specifically, our results reveal that while there 
is a difference in the process of stroke care associated with pre-
stroke mRS, this difference indicated that individuals who had 
higher pre-stroke mRS scores were more likely to be provided 
with access to evidence-based stroke care. For instance, sig-
nificantly more patients with higher pre-stroke disability scores 
received a swallow assessment and brain imaging; while there 
was no difference found in regards to pre-stroke mRS and time 
taken for admission to a SU or for brain imaging. If anything, 
the pattern of care is likely to have reduced the association 
between pre-stroke mRS and outcome. It is, therefore, reassur-
ing that the relationship between pre-stroke mRS and outcome 
appears to be based purely on the effect of premorbid disability 
on the overall impact of the stroke. Our data did not allow 
for more sophisticated analyses looking at hospital level con-
founders such as teaching hospital vs non-teaching hospital or 
staffing levels.
While our results suggest that the pre-stroke mRS has mod-
erate validity as a tool for measuring pre-stroke function, more 
work is required on this property. Confidence in the ability of the 
pre-stroke mRS to detect premorbid disability is low and Bruno 
and Switzer (22) have gone as far as to say that the pre-stroke 
mRS is not fit for purpose in this regard. Future studies that focus 
on comparing the pre-stroke mRS with a more detailed assess-
ment of pre-stroke function would help to resolve this question 
of validity.
Our study had a number of strengths. We had a large par-
ticipant pool that allowed a multitude of comparisons between 
variables enabling revealing insights into the clinical properties 
of pre-stroke mRS. Our sample was also taken from a “real 
world” patient pool of consecutive, unselected stroke admis-
sions, providing good generalizability of our results to the wider 
population.
However, we acknowledge some limitations of our study. Most 
notably, around 20% of our sample did not have pre-stroke mRS 
scores. Further analyses revealed that there were no significant 
differences of characteristics in the missing-data group compared 
with the data-intact group with the exception of stroke-type. 
Missing mRS data were more common for the severe stroke types 
(TACS and PACS). For a clinical registry, this pattern of missing 
data is not surprising. The more severe strokes will be less able 
to engage in assessments of pre-stroke status. Although these 
missing data create a potential bias, the effect is likely to have 
reduced the associations between pre-stroke mRS and outcome, 
rather than exaggerated it. Furthermore, the internal relation-
ship and effect sizes observed between pre-stroke mRS and other 
measures are not affected by missing data. We acknowledge that 
we have no detail on how pre-stroke mRS was applied at each 
site. In the absence of explicit guidance on scoring, there is the 
potential for inter-rater variability in pre-stroke mRS. However, 
potential for variation in scoring is an issue for mRS per se (16), 
and our data will reflect the way in which pre-stroke mRS is 
currently used in clinical practice, giving our results “real world” 
validity. Finally, our validation analysis is limited by an imperfect 
reference standard. Constructs such as place of residence are a 
blunt indicator of functional status.
In our analysis of the pre-stroke state, we were limited to those 
assessments that had been routinely collected in our dataset. We 
did not have comprehensive data on potentially important covari-
ates such as NIHSS. There is no single screening tool that will 
perfectly describe global functional ability. Assessments scales 
such as the Informant Questionnaire for Cognitive Decline in 
the Elderly (23) and Barthel Index (24) have been used to capture 
pre-stroke cognitive and physical ability, and it is unfortunate 
that these data were not routinely collected during the period of 
our study. Nonetheless, in the absence of a clear “gold standard” 
of pre-stroke function, the correlations with all of our measures 
in combination provides us with confidence in our validation 
method.
Based on our findings, we offer guidance for clinicians and 
researchers. As a standard mRS is only a moderately valid 
measure of pre-stroke function, we would caution against using 
this as the sole criterion for assessing suitability for research or 
for interventions. To try and improve consistency, we would 
recommend following published guidance and best practice 
in assessment (14). A more comprehensive assessment of pre-
stroke function could include measures of ability to perform 
activities of daily living and cognitive function. These assess-
ments need not necessarily add substantial time to assessment, 
for example, a short-form Barthel Index for use in stroke has 
been described (25). We would encourage greater use of pre-
stroke measures in clinical practice, our data on the prognostic 
utility of mRS remind us of the importance of considering the 
pre-stroke state.
We recognize plausible methods to improve the validity of pre-
stroke assessment, and future research could focus on these areas. 
If we continue to use mRS, there may be scope to further opera-
tionalize the assessment. Structured questionnaire approaches to 
mRS have been described (26) and a similar approach to pre-
stroke mRS could have utility. As mRS was never designed as a 
tool to measure pre-stroke function, perhaps we should move to 
a more relevant measure. There is increasing interest in tools to 
describe frailty (27) and these may have particular utility in an 
older adult stroke cohort.
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cOnclUsiOn
In summary, we have assessed the prognostic predictability of the 
pre-stroke mRS and its validity as a measure of pre-stroke func-
tion. In combination, these results highlight that the pre-stroke 
mRS can reliably be employed as a tool to assist clinicians in 
service delivery and planning. We found that the pre-stroke mRS 
is a moderately valid measure of pre-stroke disability and a robust 
predictor of poststroke prognosis. In combination, these results 
highlight that the pre-stroke mRS can reliably be employed as 
a tool to assist clinicians in service delivery and planning. The 
robust nature of the relationship between pre-stroke mRS and 
a number of different outcomes suggests that the pre-stroke 
mRS not only give an insight into likely mortality or duration 
in hospital but may also predict the probability of institutional 
care that patients will need to be taken into care poststroke, as 
well as potential poststroke complications experienced during 
the recovery period. Importantly, the prognostic accuracy of the 
pre-stroke mRS does not appear to be related to any variation 
in the process of care. Thus, prognostic models of stroke, which 
incorporate pre-stroke mRS are likely to have potential for future 
clinical implication.
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